KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $22.2 million.

  • Alnylam Pharmaceuticals' Long-Term Investments fell 6767.89% to $22.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $22.2 million, marking a year-over-year decrease of 6767.89%. This contributed to the annual value of $22.2 million for FY2025, which is 6767.89% down from last year.
  • Alnylam Pharmaceuticals' Long-Term Investments amounted to $22.2 million in Q4 2025, which was down 6767.89% from $51.3 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Long-Term Investments high stood at $68.6 million for Q4 2024, and its period low was $22.2 million during Q4 2025.
  • Moreover, its 5-year median value for Long-Term Investments was $49.4 million (2022), whereas its average is $49.8 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Long-Term Investments soared by 6537.92% in 2021 and then crashed by 6767.89% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Long-Term Investments (Quarter) stood at $40.9 million in 2021, then rose by 20.78% to $49.4 million in 2022, then grew by 0.0% to $49.4 million in 2023, then surged by 38.88% to $68.6 million in 2024, then tumbled by 67.68% to $22.2 million in 2025.
  • Its Long-Term Investments was $22.2 million in Q4 2025, compared to $51.3 million in Q3 2025 and $68.6 million in Q2 2025.